Yokoyama Osamu, Miwa Yoshiji, Oyama Nobuyuki, Aoki Yoshitaka, Ito Hideaki, Akino Hironobu
Department of Urology, Faculty of Medical Science, University of Fukui, Fukui, Japan.
J Urol. 2007 Nov;178(5):2208-12. doi: 10.1016/j.juro.2007.06.044. Epub 2007 Sep 17.
Antimuscarinic drugs increase bladder capacity without prominent side effects such as urinary retention even when administered to patients with mild to moderate bladder outlet obstruction. Some mechanisms might exist in the urethra to compensate for the emptying function of the detrusor after the administration of antimuscarinic drugs. We investigated the influence of the antimuscarinic drug propiverine (Taiho Pharmaceutical, Tokyo, Japan) on urethral function.
Urethral pressure and rhythmic bladder pressure were simultaneously monitored in urethane anesthetized female Sprague-Dawley rats. Prostaglandin E(2) was continuously administered intravesically or intraurethrally to induce detrusor overactivity. To eliminate the influence of bladder activity and monitor urethral baseline pressure isovolumetric pressure of the urethra was then recorded after cystectomy and ligation of the external urethral meatus. Furthermore, in vitro contractile responses of the urethral circular smooth muscle to field stimulation were examined in the presence of propiverine, tamsulosin (Taiho Pharmaceutical), verapamil, omega-conotoxin and atropine (Sigma).
Intravesical or intraurethral administration of prostaglandin E(2) significantly decreased the bladder contraction interval by 10.7% and 36.0%, respectively. Intra-arterial administration of 2 x 10(2) nM/kg propiverine significantly increased the bladder contraction interval in rats receiving intraurethral prostaglandin E(2) by 81.8% but it had no marked effect on rats receiving intravesical prostaglandin E(2). Significant decreases in urethral baseline pressure were found after propiverine administration. Field stimulation induced contraction was inhibited by propiverine and verapamil but not by tamsulosin, omega-conotoxin or atropine.
These results suggest that the inhibitory effects of propiverine are more prominent in rats with detrusor overactivity induced by intraurethral prostaglandin E(2) than by intravesical prostaglandin E(2). Propiverine may compensate for detrusor function by decreasing urethral resistance in the voiding phase.
抗毒蕈碱药物可增加膀胱容量,且即便用于轻至中度膀胱出口梗阻患者时也不会产生诸如尿潴留等明显副作用。在抗毒蕈碱药物给药后,尿道中可能存在某些机制来代偿逼尿肌的排空功能。我们研究了抗毒蕈碱药物丙哌维林(日本东京大鹏药品工业株式会社生产)对尿道功能的影响。
在氨基甲酸乙酯麻醉的雌性斯普拉格-道利大鼠中同时监测尿道压力和膀胱节律性压力。经膀胱或经尿道持续给予前列腺素E₂以诱导逼尿肌过度活动。为消除膀胱活动的影响并监测尿道基线压力,在膀胱切除及尿道外口结扎后记录尿道的等容压力。此外,在丙哌维林、坦索罗辛(日本东京大鹏药品工业株式会社生产)、维拉帕米、ω-芋螺毒素和阿托品(西格玛公司生产)存在的情况下,检测尿道环形平滑肌对场刺激的体外收缩反应。
经膀胱或经尿道给予前列腺素E₂分别使膀胱收缩间隔显著缩短10.7%和36.0%。动脉内给予2×10² nM/kg丙哌维林使接受经尿道前列腺素E₂的大鼠的膀胱收缩间隔显著延长81.8%,但对接受经膀胱前列腺素E₂的大鼠无明显影响。给予丙哌维林后尿道基线压力显著降低。场刺激诱导的收缩受到丙哌维林和维拉帕米的抑制,但不受坦索罗辛、ω-芋螺毒素或阿托品的抑制。
这些结果表明,丙哌维林对经尿道前列腺素E₂诱导逼尿肌过度活动的大鼠的抑制作用比对经膀胱前列腺素E₂诱导逼尿肌过度活动的大鼠更为显著。丙哌维林可能通过在排尿期降低尿道阻力来代偿逼尿肌功能。